再発性または難治性の多発性骨髄腫に対するダラツムマブによる早期アクセス治療

基本情報

NCT ID

NCT02477891

ステータス

承認済み・市販化

試験のフェーズ

-

試験タイプ

拡大アクセス

目標被験者数

-

治験依頼者名

Janssen Research & Development, LLC

概要

The objective of this study is to provide early access to daratumumab treatment and collect additional safety data while the medication is not commercially available or available through another protocol for subjects with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or whose disease is double refractory to both a PI and an IMiD.

対象疾患

介入

依頼者（Sponsor）